Skye Bioscience (SKYE) Divestments (2024 - 2025)
Skye Bioscience (SKYE) posted quarterly Divestments of $179987.0 for Q4 2025, up 28.16% year-over-year from $140434.0 in Q4 2024, and up 96.92% quarter-over-quarter from $91400.0 in Q3 2025.
Skye Bioscience (SKYE) Divestments (2024 - 2025) Analysis & Trends
Skye Bioscience (SKYE) has reported Divestments for 2 consecutive years, with $179987.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Divestments rose 28.16% year-over-year to $179987.0; the TTM figure through Dec 2025 stood at $360750.0 (down 73.44% YoY), while the FY2025 annual figure was $360750.0, down 73.44% from the prior year.
- Divestments climbed to $179987.0 in Q4 2025 per SKYE's latest filing, from $91400.0 in the prior quarter.
- Across five years, Divestments topped out at $1.1 million in Q1 2024 and bottomed at $72837.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -13.21 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 179,987.00 |
| Sep 30, 2025 | 91,400.00 |
| Jun 30, 2025 | 89,363.00 |
| Dec 31, 2024 | 140,434.00 |
| Sep 30, 2024 | 72,837.00 |
| Mar 31, 2024 | 1.15 Mn |